Literature DB >> 193525

Treatment of hypertriglyceridemia with metformin. Effectiveness and analỳsis of results.

C R Sirtori, E Tremoli, M Sirtori, F Conti, R Paoletti.   

Abstract

The triglyceride-lowering effect of metformin (N,N-dimethylbiguanide) was tested in a series of patients with stable hypertriglyceridemia (types IIB, III and IV) and with variable degrees of glucose intolerance. Metformin caused a 38% mean decrease of plasma triglycerides. A selective decrease of very low density lipoprotein cholesterol was observed without reciprocal increase of low density lipoproteins. Thirty patients completed the study. Eighteen, who showed a hypotriglyceridemic effect exceeding 30%, were considered as "Responders"; the other 12, where the effect was negligible, were considered as "Non-Responder". Analysis of the pre-and post-treatment glucose tolerance tests of Responders and Non-Responders showed that the former had, on the average, a normal glucose tolerance and insulin secretion, whereas the latter had an impaired glucose tolerance with increased insulin secretion. These parameters were only slightly modified by metformin. The conclusions of this study support the hypothesis that biguanides exert a triglyceride-lowering effect by decreasing lipoprotein secretion, independent of changes in glucose tolerance and/or insulin secretion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 193525     DOI: 10.1016/0021-9150(77)90125-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  11 in total

Review 1.  [Value of biguanide in therapy of diabetes mellitus].

Authors:  E Haupt; U Panten
Journal:  Med Klin (Munich)       Date:  1997-08-15

Review 2.  Treatment of diabetes: the effect on serum lipids and lipoproteins.

Authors:  P K Merrin; R S Elkeles
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

3.  The direct effects of metformin on platelet function in vitro.

Authors:  R De Caterina; P Marchetti; W Bernini; R Giannarelli; D Giannessi; R Navalesi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Effect of plasma metformin concentrations on serum lipid levels in type II diabetic patients.

Authors:  P Marchetti; L Benzi; M Cerri; P Cecchetti; R Giannarelli; M Giannecchini; G Di Cianni; R Cristofani; R Miccoli; A Bertolotto
Journal:  Acta Diabetol Lat       Date:  1988 Jan-Mar

Review 5.  Cardiovascular safety profile of currently available diabetic drugs.

Authors:  Komola Azimova; Zinnia San Juan; Debabrata Mukherjee
Journal:  Ochsner J       Date:  2014

6.  Pharmacokinetics of metformin after intravenous and oral administration to man.

Authors:  P J Pentikäinen; P J Neuvonen; A Penttilä
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 7.  Pharmacological control of hypertriglyceridemia.

Authors:  G Franceschini; R Paoletti
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

8.  A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family.

Authors:  G Franceschini; C R Sirtori; A Capurso; K H Weisgraber; R W Mahley
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

Review 9.  Treatment of non-insulin-dependent diabetes mellitus and its complications. A state of the art review.

Authors:  A Ilarde; M Tuck
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

10.  Effect of metformin on insulin binding to receptors in cultured human lymphocytes and cancer cells.

Authors:  V Pezzino; V Trischitta; F Purrello; R Vigneri
Journal:  Diabetologia       Date:  1982-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.